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Continuous Infusion May Improve the Efficacy of Vancomycin in Treatment
of Experimental Endocarditis Due to Heterogeneous
Vancomycin-Intermediate Staphylococcus aureus
We read with interest the paper of Entenza and coworkers
suggesting failure of continuous vancomycin infusion against
experimental endocarditis due to heterogeneous vancomycin-
intermediate Staphylococcus aureus (hVISA) and VISA (1).
In that study, it was stated that continuous vancomycin in-
fusion for 5 days was unsuccessful, as 20 mg/liter was barely
active against hVISA PC1 (6 of 13 sterile vegetations) and 40
mg/liter failed against VISA PC3 (2 of 9 sterile vegetations).
Generally speaking, we agree that in this experimental model
vancomycin led to suboptimal treatment of VISA infection;
however, we believe that some findings related to the role that
continuous infusion may have in improving the outcome of
vancomycin treatment of hVISA infections deserve attention.
Indeed, in the hVISA PC1 model (vancomycin MIC, 2 mg/
liter), there was a misinterpretation of the results, since it
appears from Fig. 1 in that paper that the number of sterile
vegetations obtained by continuous infusion was higher than
stated (7/13 and not 6/13). More importantly, compared with
intermittent vancomycin administration (peak and trough lev-
els of at least 50 and 10 mg/liter, respectively), continuous
infusion with a constant serum drug concentration of 20 mg/
liter was significantly more effective in sterilizing hVISA PC1
vegetations (54% versus 18%, P  0.05). Although fewer than
100% of the vegetations were sterilized, it must be highlighted
that continuous infusion was the only bactericidal regimen,
since it led to a more-than-4-log reduction of the mean bacte-
rial burden in the vegetations at day 5 compared to that in the
controls (3.57  2.1 versus 7.64  0.4 log10 CFU/g [P 
0.001]), which is different from what occurred with intermittent
infusion (6.82  3.1 log10 versus 7.64  0.4 log10 CFU/g [no
statistically significant difference]).
These data suggest that continuous infusion of vancomycin
may significantly improve the treatment outcome of experi-
mental endocarditis due to hVISA. Indeed, the incomplete
sterilization seen even after 5 days of continuous vancomycin
infusion may be in line with the time-dependent activity of this
glycopeptide, which may take a much longer time for complete
healing to occur, especially if the bacteria are embedded in
biofilm (2). However, it is worth noting that by ensuring that
the concentration persistently exceeds a value of at least four
to five times the MIC, this strategy may also reduce the selec-
tive pressure due to very low trough levels (3) and may avert
the development of frank vancomycin resistance, even in cases
of long-term treatment (4).
Considering that a recent systematic review and meta-anal-
ysis of the clinical significance of hVISA isolates (5) showed
that hVISA infections were associated with a glycopeptide
failure rate 2.37-fold greater than that obtained with vancomycin-
susceptible S. aureus infections, we do believe that these experi-
mental data may support the idea that continuous infusion may
be worthwhile with the intent to decrease the failure rate of
vancomycin treatment of humans with hVISA infections.
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Authors’ Reply
We thank Pea et al. for their comment on our article on the
efficacy of continuous vancomycin infusion against experimen-
tal endocarditis due to vancomycin-intermediate Staphylococ-
cus aureus (VISA) (2). Pea et al. dispute our interpretation
that continuous vancomycin infusion was poorly effective
against both heterogeneously resistant VISA (hVISA) and ho-
mogeneously resistant VISA. They consider that the relative
activity of continuous vancomycin infusion against hVISA in
animals indicates that it might also be useful in humans. In
brief, our data show that sequential (twice a day) vancomycin
treatment was successful in animals infected with vancomycin-
susceptible S. aureus but completely failed against hVISA (van-
comycin MIC  2 mg/liter) and VISA (vancomycin MIC  8
mg/liter). In comparison, continuous infusion providing con-
stant serum drug levels of 10 times the MIC tended to be more
effective against hVISA (ca. 50% cure rate) but also failed
against VISA (ca. 20% cure rate). Moreover, in spite of some
activity, continuous infusion selected for derivatives of both
hVISA and VISA with increased resistance levels.
We do agree with the first assertion of Pea et al. that
4496
continuous vancomycin infusion had some activity against
hVISA. This is specifically stated in the article as follows:
“The present study demonstrates that continuous infusion
of vancomycin, at concentrations affording optimal constant
serum levels of 10 times the MIC for the infecting organism,
was more effective than standard sequential treatment but
relatively not optimal against experimental endocarditis due
to hVISA.” On the other hand, we do not share their opti-
mism about the safe use of such a regimen in clinics. Indeed,
similar experimental results (regarding limited success and
resistance selection) were previously obtained with quino-
lones and precisely predicted the later occurrence of treat-
ment failures and resistance selection with these drugs in
humans (1, 3). Therefore, we do not recommend continuous
vancomycin infusion as an optimal choice for use against
hVISA because its limited success and especially the prompt
selection of resistance make it unsafe.
REFERENCES
1. Entenza, J. M., Y. A. Que, J. Vouillamoz, M. P. Glauser, and P. Moreillon.
2001. Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against exper-
imental endocarditis due to methicillin-resistant Staphylococcus aureus ex-
pressing various degrees of ciprofloxacin resistance. Antimicrob. Agents Che-
mother. 45:3076–3083.
2. Entenza, J. M., T. R. Veloso, J. Vouillamoz, M. Giddey, and P. Moreillon.
2011. Failure of vancomycin continuous infusion against experimental endo-
carditis due to vancomycin-intermediate Staphylococcus aureus. Antimicrob.
Agents Chemother. 55:385–387.
3. Entenza, J. M., J. Vouillamoz, M. P. Glauser, and P. Moreillon. 1997. Levo-
floxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of
experimental endocarditis due to methicillin-susceptible or -resistant Staphy-
lococcus aureus. Antimicrob. Agents Chemother. 41:1662–1667.
J. M. Entenza*
T. R. Veloso
J. Vouillamoz
M. Giddey
P. Moreillon
Department of Fundamental Microbiology
Biophore—University of Lausanne
CH-1015 Lausanne, Switzerland
*Phone: 41-21-6925612
Fax: 41-21-6925605
E-mail: jose.entenza@unil.ch
VOL. 55, 2011 LETTERS TO THE EDITOR 4497
